Phio Pharmaceuticals Insider Ronald Todd Plott Buys $15.2K of Stock
Ronald Todd Plott bought 18,300 shares of Phio Pharmaceuticals Corp. at $0.83 a share, worth $15.2K in total on Nov 9, 2026. Shares held after the trade: 60,300 (+43.6%).
Phio Pharmaceuticals Chairman, Pres. & CEO Robert J. Bitterman Buys $20.5K of Stock
Robert J. Bitterman, Chairman, Pres. & CEO, bought 25,000 shares of Phio Pharmaceuticals Corp. at $0.82 a share, worth $20.5K in total on Nov 9, 2026. Shares held after the trade: 789,871 (+3.3%).
Phio Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $10.6 million. The company achieved key milestones for its PH-762 program, including the completion of commercial-scale cGMP manufacturing and the submission of Phase 1b clinical data to the FDA in preparation for a Phase 2b study initiation expected in Q1 2027.
Term
Q3 2026
“We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study initiation. Commercial-scale drug substance manufacturing was completed and shipped to our drug product manufacturer in preparation for making clinical trial supply material. We have submitted detailed information to FDA providing final analysis of our Phase 1b clinical trial and the fundamentals of our intended upcoming Phase 2b study.”
Robert J. Bitterman, President and Chief Executive Officer
Phio Pharmaceuticals Corp. reported a net loss of $12.3 million for the nine months ended September 30, 2026, compared to $6.3 million in the prior year period, primarily driven by a significant increase in research and development expenses. As of September 30, 2026, the company held $10.6 million in cash and cash equivalents, down from $21.0 million at the end of 2025.